作者想感谢约翰马斯顿畜牧业专家和博士马可波罗A. Passini技术援助，在这个项目的早期阶段。这项工作是由资助的​​国立卫生研究院慢性淋巴细胞白血病（R01NS41584; R01HD054413）。

1。侧脑室注射<ol><li>第一步是准备注入股市的解决方案，这些解决方案是病毒载体，质粒DNA，药物，应在无菌条件下注入。 </li><li>混合0.05％的注射部位的可视化W / V台盼蓝的PBS所需滴度的病毒载体（5-7微升总）。 </li><li>质粒DNA溶液（5升微升总）包含的D -（+） - 葡萄糖20％（W / V）（1μL），台盼蓝（0.05％），PBS（1μL），质粒（约5〜G /〜L ）（2〜L）和2.5 kDa的线性PEI均聚物（150毫米）（1〜L）。 </li><li>通过1-2分钟，低温麻醉，固定的PND 2新生儿。 </li><li>使用此注射针微升校准灭菌的玻璃微管，是通过长管连接到一个3毫升3毫升汉密尔顿注射器。 </li><li>打破（锅铲）调整为2毫米渗透入颅的针头的针尖。斜中含有的微量注射液管将针头。仔细地拉动注射器的柱塞装入针注射液。 </li><li>摄取的解决方案后，脱离管注射器;拉柱塞进一步，然后再次连接到针。 </li><li>在右手拇指和食指之间保持的针头和地方注射器柱塞摸右手手掌的中指和无名指之间。 </li><li>抓紧背后的头部皮肤使用左手和地方在光纤光照亮相关的解剖结构，可作为指导使用固定的鼠标。 </li><li>针2毫米深，垂直插入颅骨表面，在一个位置约0.25毫米，横向的矢状缝和0.50-0.75毫米，喙新生儿冠状动脉缝合（ 图 1A）。然后，用手掌推柱塞右手非常缓慢和谨慎。监测破裂的船只或面部肿胀。 </li><li>取出针15秒后停止活塞运动，以防止回流。 </li><li>要恢复，保持5-10分钟的小鼠，在加热的容器中，直到恢复运动和一般的响应。 </li></ol> 2。通过时间/面部静脉的静脉注射<ol><li>被注入的解决方案应该是准备在1:100稀释，并辅以过滤绿色食用色素和无菌条件下注入。 </li><li>将一个小塑料露儿100μL玻璃汉密尔顿注射器年底。露儿，附加33计0.25英寸的注射针。确保所有部件连接牢固。 </li><li>被注入量装入注射器，确保在注射器注射入​​血管的空气，没有空气是致命的。它往往是有益的吸管要你们一块的封口膜注射量。这允许摄取到注射器的解决明确的可视化。 </li><li>一个极小的景象透射是用来方便地可视化的颞浅静脉，或在新生儿的面部静脉（图2A）。注射前，确保新生儿使用手术磁带的透射。纱布应该放在新生儿和破坏动物的皮肤，以防止磁带的磁带。安全的动物，在其一侧的透射，确保磁带并不妨碍呼吸。新生儿的脖子上，应轻轻打开，使面部静脉是很容易看到，贴在鼻子应该是稳定的头部。 </li><li>使用2.25X头带放大镜，以便更容易可视化，慢慢地插入静脉的针。使针头应保持可见皮下的静脉是很肤浅的。 </li><li>静脉缓慢注入溶液的体积。绿色染料允许注射容易可视化。 </li><li>前等待15秒，取出针有一个完全压下注射器的柱塞和驱逐剩余的解决方案，由于极其狭窄的针孔之间的滞后。 </li><li>取出针后，用纱布注射部位施加压力，直到出血停止。 </li><li>监测新生儿窘迫的迹象。正确的注射后，没有明显的窘迫应得到遵守。新生儿应给予恢复它返回到笼前约5分钟。 </li><li>针/注射器单位之间的注射用PBS冲洗针的血液会很快堵塞由于小口径。 </li></ol> 3。代表性的成果： 侧脑室注射：大脑可以在不同的时间点注射后收获和可视化，以证明成功的注射技术。如果不添加染料注射液，将很难​​检查中的准确性jection。适当注射脑室之一，将允许在注射侧大脑的台盼蓝分布，注射后（ 图 1B）约10-15分钟。一台盼蓝均匀分布在左，右大脑半球和嗅球将可见注射后约60分钟（ 图1C）。这是由于连接将允许传播到相邻的脑室蓝色染料的脑室。精确的注射，也可以由散布在约12小时内注射后（ 图1D）延髓中央椎管蓝色染料的可视化。不准确的注射可以区分蓝色缺乏大脑半球。在这种情况下，进针深度是不足够的注射液有可能分布在皮肤下。另一种可能性是，针穿透过深在大脑中，从而超越了脑室及脑室底下掏空的解决方案是传递。 静脉注射：准确，高效的时间/面部静脉注射，可以可视化紧随注射。由于注入的解决方案，绿色染料允许可视化解决方案的进入和流经面部静脉（ 图2A）。此外，改变皮肤颜色的鼠标将遵守以下注射。新生儿正常的粉红色转换为绿色，由于绿色食品染料注射液存在（ 图2B） 。观察新生儿的绿色变化的程度取决于所使用的染料浓度。注射，并在实践期间的简单的可视化，1:50稀释建议。然而，显着地改变肤色，结果往往是小狗被母亲拒绝，因此，去除的染料或一个显著减少的浓度应在实验程序考虑。一个不准确的注入将导致绿色染料的积累，在注射部位的皮肤下。注射不完整的，它发生时没有完全插入静脉内针开幕，在静脉中流动时，会出现一些解决方案和一些积聚在皮肤下。如果发生此种情况，应插入针入血管。 <img src="/files/ftp_upload/2968/2968fig1.jpg" alt="图1"/> 图1示范成功的ICV PDN2小鼠注射。 一个利用侧脑室注射入脑室注射部位）示意图B）从ICV的大脑注入左心室与台盼蓝的PBS小狗，合影留念注射后15分钟，C左心室）侧脑室脑注射台盼蓝的PBS小狗，合影留念注射后60分钟，D）延髓中央椎管在侧脑室注射用台盼蓝的PBS小狗左心室上，采取12小时注射后的照片。 <img src="/files/ftp_upload/2968/2968fig2.jpg" alt="图2"/> 图2示范成功的第四PDN2小鼠注射。静脉注射剂使用的面部静脉）示意图 B）小狗注射绿色染料第四的PBS相比，联合国注入littermate，照片立即注射后。

<ol>
	<li>Blanchette, M., Fortin, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Blood-brain+barrier+disruption+in+the+treatment+of+brain+tumors.">Blood-brain barrier disruption in the treatment of brain tumors.</a> Methods Mol. Biol. 686, 447-463 (2011).</li><li>Foust, K. D., Kaspar, B. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Over+the+barrier+and+through+the+blood:+to+CNS+delivery+we+go.">Over the barrier and through the blood: to CNS delivery we go.</a> Cell Cycle. 24, 4017-4018 (2009).</li><li>Snyder, E. Y., Taylor, R. M., Wolfe, J. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Neural+progenitor+cell+engraftment+corrects+lysosomal+storage+throughout+the+MPS+VII+mouse+brain.">Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain.</a> Nature. 374, 367-370 (1995).</li><li>Passini, M. A., Wolfe, J. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Widespread+gene+delivery+and+structure-specific+patterns+of+expression+in+the+brain+after+intraventricular+injections+of+neonatal+mice+with+an+adeno-associated+virus+vector.">Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.</a> J. Virol. 24, 12382-12392 (2001).</li><li>Kienstra, K. A., Freysdottir, D., Gonzales, N. M., Hirschi, K. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Murine+neonatal+intravascular+injections:+modeling+newborn+disease.">Murine neonatal intravascular injections: modeling newborn disease.</a> J. Am. Assoc. Lab. Anim. Sci. 46, 50-54 (2007).</li><li>Sands, M. S., Barker, J. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Percutaneous+intravenous+injection+in+neonatal+mice.">Percutaneous intravenous injection in neonatal mice.</a> Lab. Anim. Sci. 49, 328-330 (1999).</li><li>Foust, K. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rescue+of+the+spinal+muscular+atrophy+phenotype+in+a+mouse+model+by+early+postnatal+delivery+of+SMN.">Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.</a> Nat. Biotechnol. 28, 271-274 (2010).</li><li>Foust, K. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intravascular+AAV9+preferentially+targets+neonatal+neurons+and+adult+astrocytes.">Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.</a> Nat. Biotechnol. 27, 59-65 (2009).</li><li>Passini, M. A., Watson, D. J., Wolfe, J. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Gene+delivery+to+the+mouse+brain+with+adeno-associated+virus.">Gene delivery to the mouse brain with adeno-associated virus.</a> Methods Mol. Biol. 246, 225-236 (2004).</li><li>Coady, T. H., Lorson, C. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Trans-splicing-mediated+improvement+in+a+severe+mouse+model+of+spinal+muscular+atrophy.">Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.</a> J. Neurosci. 30, 126-130 (2010).</li><li>Baughan, T. D., Dickson, A., Osman, E. Y., Lorson, C. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Delivery+of+bifunctional+RNAs+that+target+an+intronic+repressor+and+increase+SMN+levels+in+an+animal+model+of+spinal+muscular+atrophy.">Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.</a> Hum. Mol. Genet. 18, 1600-1611 (2009).</li><li>Coady, T. H., Baughan, T. D., Shababi, M., Passini, M. A., Lorson, C. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+a+single+vector+system+that+enhances+trans-splicing+of+SMN2+transcripts.">Development of a single vector system that enhances trans-splicing of SMN2 transcripts.</a> PLoS One. 3, e3468-e3468 (2008).</li><li>Dickson, A., Osman, E., Lorson, C. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Negatively-Acting+Bifunctional+RNA+Increases+Survival+Motor+Neuron+in+vitro+and+in+vivo.">Negatively-Acting Bifunctional RNA Increases Survival Motor Neuron in vitro and in vivo.</a> Hum. Gene. Ther. 19, 1307-1315 .</li><li>Mattis, V. B., Ebert, A. D., Fosso, M. Y., Chang, C. W., Lorson, C. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Delivery+of+a+read-through+inducing+compound,+TC007,+lessens+the+severity+of+a+spinal+muscular+atrophy+animal+model.">Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model.</a> Hum. Mol. Genet. 18, 3906-3913 (2009).</li><li>Williams, J. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Oligonucleotide-mediated+survival+of+motor+neuron+protein+expression+in+CNS+improves+phenotype+in+a+mouse+model+of+spinal+muscular+atrophy.">Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.</a> J. Neurosci. 29, 7633-7638 (2009).</li><li>Passini, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CNS-targeted+gene+therapy+improves+survival+and+motor+function+in+a+mouse+model+of+spinal+muscular+atrophy.">CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.</a> J. Clin. Invest. 120, 1253-1264 (2010).</li><li>Shababi, M., Glascock, J., Lorson, C. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Combination+of+SMN+Trans-Splicing+and+a+Neurotrophic+Factor+Increases+the+Life+Span+and+Body+Mass+in+a+Severe+Model+of+Spinal+Muscular+Atrophy.">Combination of SMN Trans-Splicing and a Neurotrophic Factor Increases the Life Span and Body Mass in a Severe Model of Spinal Muscular Atrophy.</a> Hum. Gene. Ther. 22, 1-10 (2010).</li></ol>

没有利益冲突的声明。

疾病的小鼠模型的研究往往需要药物或其他物质的管理，新生儿。在这段视频中，我们展示了一步一步程序，利用侧脑室（ICV）注射CNS涉及两种类型的注射战略目标的中枢神经系统，可用于：1）直接注射;或2）静脉注射针对时间/面部静脉。这些注射的时间是非常重要的。由于ICV注射写意，头骨必须相对可塑性。这种类型的注射是唯一可能通过的第一个星期的生活，变得越来越具有挑战性的和有害...

<table border="1"><tbody><tr><th>试剂名称</th><th>公司</th><th>目录编号</th><th>评论（可选） </th></tr><tr><td>绿色食用色素</td><td>麦考密克</td><td> N / A </td><td>必须过滤</td></tr><tr><td>汉密尔顿玻璃注射器（100微升） </td><td>西格玛Aldrick </td><td> 20702 </td><td></td></tr><tr><td> LuerMxF主题风格的白色尼龙</td><td>小零件， </td><td> VPLF - LC78 - 1 - 25 </td><td></td></tr><tr><td>细针距注射针头</td><td>波普尔</td><td> 7111 </td><td>尺寸：33号（SWG）× ¼“（6.35毫米） </td></tr><tr><td>凌晨视透射</td><td>呼吸</td><td> 1017920 </td><td></td></tr><tr><td> 2.25X头戴放大镜</td><td> MagEyes </td><td>型号5 </td><td>选择适合个人喜好的放大倍率</td></tr></tbody></table>

delivery of therapeutic agents through intracerebroventricular (icv) and intravenous (iv) injection in mice

尽管血脑屏障的保护作用，起着屏蔽大脑，中枢神经系统（CNS）的访问限制， 设计 1,2神经退行性疾病的潜在疗法的失败中最常见的结果。神经退行性疾病，如脊髓性肌萎缩症（SMA），下运动神经元受到影响，可以极大地受益，从引进治疗药物进入中枢神经系统。此视频的目的是为了演示两种不同的注射范式传递到新生小鼠出生后不久，治疗材料。其中一个方法是直接注射入脑侧脑室（侧脑室）材料传递到中枢神经系统通过脑脊液3,4结果。第二种方法是一个时间的静脉注射（静脉注射），可以引入不同的循环系统的疗法，导致全身交付，包括中枢神经系统5。如果一个合适的病毒载体和病毒血清型是利用广泛的中枢神经系统传导是可以实现的的。颞静脉注射的可视化和利用是可行的出生后第6天。但是，如果传递的材料是为了达到中枢神经系统，这些注射应采取血脑屏障，同时由于其不成熟的状态，更渗透，最好到产后第2天之前。充分发展的血脑屏障，极大地限制了静脉交付的成效。一次手术aptitude是实现两个输送系统是简单而有效的的。他们不需要任何广泛的手术设备，可以由一个人完成。然而，这些技术并非没有挑战。产后第2天的幼崽和随后的小目标领域的体积小，可以使注射难以执行，最初具有挑战性的复制。

Watch this Scientific Journal Video about Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice at JoVE.com

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

本文演示了两种非常不同的方法：注射入脑（脑室）和2）全身（静脉注射）1）引入到中央的新生小鼠的中枢神经系统治疗药物。

交付的治疗药物通过侧脑室（ICV）和静脉（IV）注射液在小鼠

Despite the protective role that blood brain barrier plays in shielding the brain, it limits the access to the central nervous system (CNS) which most ...

delivery-therapeutic-agents-through-intracerebroventricular-icv

Research

JoVE Journal

Medicine

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

58.7K 次观看.  University of Missouri. 本文演示了两种非常不同的方法：注射入脑（脑室）和2）全身（静脉注射）1）引入到中央的新生小鼠的中枢神经系统治疗药物。

视频: Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Although in vitro screens are essential for the initial identification of candidate therapeutic agents, a rigorous assessment of the drug's ability to inhibit tumor growth must be performed in a suitable animal model. The type of animal model that is best for this purpose is a topic of intense discussion. Some evidence indicates that preclinical trials examining drug effects on tumors arising in transgenic mice are more predictive of clinical outcome1and so candidate therapeutic agents are often tested in these models. Unfortunately, transgenic models are not available for many tumor types. Further, transgenic models often have other limitations such as concerns as to how well the mouse tumor models its human counterpart, incomplete penetrance of the tumor phenotype and an inability to predict when tumors will develop.
Consequently, many investigators use xenograft models (human tumor cells grafted into immunodeficient mice) for preclinical trials if appropriate transgenic tumor models are not available. Even if transgenic models are available, they are often partnered with xenograft models as the latter facilitate rapid determination of therapeutic ranges. Further, this partnership allows a comparison of the effectiveness of the agent in transgenic tumors and genuine human tumor cells. Historically, xenografting has often been performed by injecting tumor cells subcutaneously (ectopic xenografts). This technique is rapid and reproducible, relatively inexpensive and allows continuous quantitation of tumor growth during the therapeutic period2. However, the subcutaneous space is not the normal microenvironment for most neoplasms and so results obtained with ectopic xenografting can be misleading due to factors such as an absence of organ-specific expression of host tissue and tumor genes. It has thus been strongly recommended that ectopic grafting studies be replaced or complemented by studies in which human tumor cells are grafted into their tissue of origin (orthotopic xenografting)2. Unfortunately, implementation of this recommendation is often thwarted by the fact that orthotopic xenografting methodologies have not yet been developed for many tumor types.
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive sarcomas that occur sporadically or in association with neurofibromatosis type 13and most commonly arise in the sciatic nerve4. Here we describe a technically straightforward method in which firefly luciferase-tagged human MPNST cells are orthopically xenografted into the sciatic nerve of immunodeficient mice. Our approach to assessing the success of the grafting procedure in individual animals and subsequent non-biased randomization into study groups is also discussed.

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described. The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.

原位Xenografting人类荧光素酶标记的恶性外周神经鞘瘤细胞在体内测试候选治疗药物

Although in vitro screens are essential for the initial identification of candidate therapeutic agents, a rigorous assessment of the drug's ability to ...

科研

医学

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Diseases of the retina are difficult to treat as the retina lies deep within the eye. Invasive methods of drug delivery are often needed to treat these diseases. Chronic retinal diseases such as retinal oedema or neovascularization usually require multiple intraocular injections to effectively treat the condition. However, the risks associated with these injections increase with repeated delivery of the drug. Therefore, alternative delivery methods need to be established in order to minimize the risks of reinjection. Several other investigations have developed methods to deliver drugs over extended time, through materials capable of releasing chemicals slowly into the eye. In this investigation, we outline the use of Elvax 40W, a copolymer resin, to act as a vehicle for drug delivery to the adult rat retina. The resin is made and loaded with the drug. The drug-resin complex is then implanted into the vitreous cavity, where it will slowly release the drug over time. This method was tested using 2-amino-4-phosphonobutyrate (APB), a glutamate analogue that blocks the light response of the retina. It was demonstrated that the APB was slowly released from the resin, and was able to block the retinal response by 7 days after implantation. This indicates that slow-release drug delivery using this copolymer resin is effective for treating the retina, and could be used therapeutically with further testing.

This paper details how Elvax 40W can be used as a slow-release method for drug delivery to the adult rat retina. The protocol for preparing, loading, and delivering the drug-resin complex to the eye is described.

通过40W的Elvax缓释给药的大鼠视网膜：对慢性疾病的治疗

Diseases of the retina are difficult to treat as the retina lies deep within the eye. Invasive methods of drug delivery are often needed to treat these ...

Ultrasound-guided Transthoracic Intramyocardial Injection in Mice

Murine models of cardiovascular disease are important for investigating pathophysiological mechanisms and exploring potential regenerative therapies. Experiments involving myocardial injection are currently performed by direct surgical access through a thoracotomy. While convenient when performed at the time of another experimental manipulation such as coronary artery ligation, the need for an invasive procedure for intramyocardial delivery limits potential experimental designs. With ever improving ultrasound resolution and advanced noninvasive imaging modalities, it is now feasible to routinely perform ultrasound-guided, percutaneous intramyocardial injection. This modality efficiently and reliably delivers agents to a targeted region of myocardium. Advantages of this technique include the avoidance of surgical morbidity, the facility to target regions of myocardium selectively under ultrasound guidance, and the opportunity to deliver injectate to the myocardium at multiple, predetermined time intervals. With practiced technique, complications from intramyocardial injection are rare, and mice quickly return to normal activity on recovery from anesthetic. Following the steps outlined in this protocol, the operator with basic echocardiography experience can quickly become competent in this versatile, minimally invasive technique.

Echocardiography-guided percutaneous intramyocardial injection represents an efficient, reliable, and targetable modality for the delivery of gene transfer agents or cells into the murine heart. Following the steps outlined in this protocol, the operator can quickly become competent in this versatile, minimally invasive technique.

超声引导下经皮内注射小鼠

Murine models of cardiovascular disease are important for investigating pathophysiological mechanisms and exploring potential regenerative therapies. ...

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

To date, many pharmacological agents used to treat or prevent arrhythmias in open-heart cases create undesired systemic side effects. For example, antiarrhythmic drugs administered intravenously can produce drops in systemic pressure in the already compromised cardiac patient. While performing open-heart procedures, surgeons will often either create a small port or form a pericardial cradle to create suitable fields for operation. This access yields opportunities for target pharmacological delivery (antiarrhythmic or ischemic preconditioning agents) directly to the myocardial tissue without undesired side effects.
We have developed a swine model for testing pharmacological agents for target delivery within the pericardial fluid. While fully anesthetized, each animal was instrumented with a Swan-Ganz catheter as well as left and right ventricle pressure catheters, and pacing leads were placed in the right atrial appendage and the right ventricle. A medial sternotomy was then performed and a pericardial access cradle was created; a plunge pacing lead was placed in the left atrial appendage and a bipolar pacing lead was placed in the left ventricle. Utilizing a programmer and a cardiac mapping system, the refractory period of the atrioventricular node (AVN), atria and ventricles was determined. In addition, atrial fibrillation (AF) induction was produced utilizing a Grass stimulator and time in AF was observed. These measurements were performed prior to treatment, as well as 30 min&#160;and 60 min&#160;after pericardial treatment. Additional time points were added for selected studies. The heart was then cardiopleged and reanimated in a four chamber working mode. Pressure measurements and function were recorded for 1 hr after reanimation. This treatment strategy model allowed us to observe the effects of pharmacological agents that may decrease the incidence of cardiac arrhythmias and/or ischemic damage, during and after open-heart surgery.

We have developed a swine model for the target delivery of pharmacological agents within the pericardial space/fluid. Using this approach, the relative benefits of administered agents on induced atrial fibrillation, relative refractory periods and/or ischemic protection can be investigated.

药理试验药物的疗效在心包目标交付模型在猪

To date, many pharmacological agents used to treat or prevent arrhythmias in open-heart cases create undesired systemic side effects. For example, ...

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Development of new therapeutic products requires efficacy testing in an animal model. The pulmonary route of administration can be utilized to deliver drugs locally and systemically. Evaluation of dry powder aerosols necessitates an efficient dispersion mechanism to maintain high concentrations in an exposure chamber or for direct endotracheal administration. While solutions exist to expose animals by passive inhalation to dry powder aerosols, most require masses of powder in large excess of the dose delivered. This precludes conducting early feasibility studies as insufficient drug is available at the research or early development stage to support the dose delivery requirements for conventional aerosol delivery systems. When designing an aerosol drug product, aerodynamic performance can relate directly to delivery efficiency and efficacy. Dispersion of powder into an aerosol requires energy input sufficient to overcome interparticulate forces, and particle engineering approaches can substantially improve aerosol performance. We have developed a dispersion system (dosator) which can aerosolize engineered dry powder aerosols efficiently for the purpose of direct pulmonary insufflation, dispersion into an exposure system or generation for analytical purposes.

During development of drugs for pulmonary delivery, it is necessary to evaluate pharmacokinetics and efficacy in an animal model. We present a method to build a disposable aerosol dispersion system from of-the-shelf components that can be used to administer intrapulmonary dry powder aerosol to rodents.

一次性充填机对治疗药物的肺吹入小动物

Development of new therapeutic products requires efficacy testing in an animal model. The pulmonary route of administration can be utilized to deliver ...

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

The intrinsic tropism towards brain malignancies renders stem cells as promising carriers of therapeutic agents against malignant tumors. The delivery of therapeutic stem cells via the intranasal route is a recently discovered alternative strategy, with strong potential for clinical translation, due to its non-invasive nature compared to intracranial implantation or delivery via systemic routes. The lack of blood brain barrier further strengthens the therapeutic potential of stem cells undergoing intranasal brain entry. This article summarizes the essential techniques utilized in our studies and outlines the basic principles of intranasal strategy for stem cell delivery using a mouse model of intracranial glioma xenografts. We demonstrate the optimized procedures that generate consistent and reproducible results with specific predetermined experimental parameters and offer guidelines for streamlined work flow that ensure efficient execution and reliable experimental outcome. The article is designed to serve as a baseline for further experimental customization based on hypothesis, stem cell types, or tumor specifics.

Stem cells are promising therapeutic carriers to treat brain tumors due to their intrinsic tumor tropism. Non-invasive intranasal stem cell delivery bypasses the blood brain barrier and demonstrates strong potential for clinical translation. This article summarizes the basic principles of intranasal stem cell delivery in a mouse model of glioma.

在小鼠模型中将胶质母细胞瘤治疗干细胞的鼻内递送

The intrinsic tropism towards brain malignancies renders stem cells as promising carriers of therapeutic agents against malignant tumors. The delivery of ...

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Cardiovascular disease remains the leading cause of death and disability worldwide, in part due to atherosclerosis. Atherosclerotic plaque narrows the luminal surface area in arteries thereby reducing adequate blood flow to organs and distal tissues. Clinically, revascularization procedures such as balloon angioplasty with or without stent placement aim to restore blood flow. Although these procedures reestablish blood flow by reducing plaque burden, they damage the vessel wall, which initiates the arterial healing response. The prolonged healing response causes arterial restenosis, or re-narrowing, ultimately limiting the long-term success of these revascularization procedures. Therefore, preclinical animal models are integral for analyzing the pathophysiological mechanisms driving restenosis, and provide the opportunity to test novel therapeutic strategies. Murine models are cheaper and easier to operate on than large animal models. Balloon or wire injury are the two commonly accepted injury modalities used in murine models. Balloon injury models in particular mimic the clinical angioplasty procedure and cause adequate damage to the artery for the development of restenosis. Herein we describe the surgical details for performing and histologically analyzing the modified, pressure-controlled rat carotid artery balloon injury model. Additionally, this protocol highlights how local periadventitial application of therapeutics can be used to inhibit neointimal hyperplasia. Lastly, we present light sheet fluorescence microscopy as a novel approach for imaging and visualizing the arterial injury in three-dimensions.

The rat carotid artery balloon injury mimics the clinical angioplasty procedure performed to restore blood flow in atherosclerotic vessels. This model induces the arterial injury response by distending the arterial wall, and denuding the intimal layer of endothelial cells, ultimately causing remodeling and an intimal hyperplastic response.

大鼠胡萝卜动脉压力控制段气球损伤与腹腔ventit 治疗应用

Cardiovascular disease remains the leading cause of death and disability worldwide, in part due to atherosclerosis. Atherosclerotic plaque narrows the ...

Intratracheal Administration of Dry Powder Formulation in Mice

In the development of inhalable dry powder formulations, it is essential to evaluate their biological activities in preclinical animal models. This paper introduces a noninvasive method of intratracheal delivery of dry powder formulation in mice. A dry powder loading device that consists of a 200 &#181;L gel loading pipette tip connected to an 1 mL syringe via a three-way stopcock is presented. A small amount of dry powder (1-2 mg) is loaded into the pipette tip and dispersed by 0.6 mL of air in the syringe. Because pipette tips are disposable and inexpensive, different dry powder formulations can be loaded into different tips in advance. Various formulations can be evaluated in the same animal experiment without device cleaning and dose refilling, thereby saving time and eliminating the risk of cross-contamination from residual powder. The extent of powder dispersion can be inspected by the amount of powder remaining in the pipette tip. A protocol of intubation in mouse with a custom-made light source and a guiding cannula is included. Proper intubation is one of the key factors that influences the intratracheal delivery of dry powder formulation to the deep lung region of the mouse.

Dry powder formulations for inhalation have great potential in treating respiratory diseases. Before entering human studies, it is necessary to evaluate the efficacy of the dry powder formulation in preclinical studies. A simple and noninvasive method of the administration of dry powder in mice through the intratracheal route is presented.

小鼠干粉配方的内经管理

In the development of inhalable dry powder formulations, it is essential to evaluate their biological activities in preclinical animal models. This paper ...

六君子汤：预防 UC-CRC 的有效治疗方法

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading cause of malignancy-related death. Ulcerative coloproctitis (UC) is a precancerous lesion, and UC-associated CRC (UC-CRC) is the most common subtype of CRC. Therefore, a reasonable UC-CRC model is the cornerstone and guarantee of new drug development. Traditional Chinese medicine (TCM) has been widely used in the treatment of UC-CRC due to its good efficacy. As a classic tonic prescription of TCM, Liujunzi decoction (LJZD) has been widely used in the treatment of UC-CRC. In this study, a UC-CRC model was established by combining azomethane and dextran sulfate sodium, and the LJZD was administered. The data confirmed that LJZD can effectively inhibit cancer transition in UC-CRC by using mouse body weight, colorectal length, pathological and inflammatory factors, colorectal barrier function, and cancer markers. This protocol provides a system for evaluating the efficacy of TCM in the prevention and treatment of UC-CRC.

作者聚焦： 六君子汤作为结肠直肠炎癌症的中医治疗方法

This protocol provides a mouse model of ulcerative coloproctitis-associated colorectal cancer induced by azomethane combined with dextran sulfate sodium. The model was used to evaluate the efficacy of traditional Chinese medicine compounds in the prevention and treatment of colorectal cancer.

小鼠结肠直肠炎癌症模型的建立及中药治疗效果评价

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading ...